Management of Patients with Negative ANA but Positive Anti-dsDNA Antibodies

Diagnostic Approach

For patients with negative ANA but positive anti-dsDNA antibodies, a comprehensive evaluation for systemic lupus erythematosus (SLE) is strongly recommended, as this combination can still represent true SLE in patients with high clinical suspicion 1, 2
When ANA is negative but anti-dsDNA is positive, the diagnosis will fundamentally depend on the patient's clinical characteristics, as this serological profile is uncommon but clinically significant 1, 2
Confirmation of the anti-dsDNA result using a different method is recommended, particularly using Crithidia luciliae immunofluorescence test (CLIFT) which offers high clinical specificity 1, 3
If the initial anti-dsDNA was detected using solid phase assays (SPA) like ELISA or FEIA, confirmation with CLIFT is particularly important to rule out false positives 2, 3

Test for anti-nucleosome antibodies, which may precede ANA in SLE pathogenesis and show high sensitivity (83.33%) and specificity (96.67%) for SLE 1, 2
Evaluate for antiphospholipid antibodies (anticardiolipin, anti-β2GP1, lupus anticoagulant) as 30-40% of SLE patients are positive for these antibodies 2, 4
Test for anti-extractable nuclear antigens (anti-ENA), particularly anti-Smith (Sm) antibodies which are highly specific for SLE 4, 5
Assess complement levels (C3, C4), as low levels are associated with SLE activity 4, 5
Check for anti-C1q antibodies, which are found in almost 100% of patients with active lupus nephritis 4

Patients should undergo periodic clinical follow-up as anti-dsDNA antibodies may be detected long before the development of clear clinical signs 2
Use disease activity indices such as SLEDAI (SLE Disease Activity Index) to objectively assess disease activity 4

For patients with systemic manifestations, hydroxychloroquine is recommended for arthralgia, arthritis, or constitutional symptoms 6
Short-term oral glucocorticoids may be considered for acute inflammatory manifestations 6
For organ-threatening disease, immunosuppressive agents should be considered 6
In patients with lupus nephritis, monitor anti-dsDNA levels and complement regularly as these correlate with disease activity 4

If SLE is diagnosed, use anti-dsDNA (not ANA) to monitor disease activity 3, 4
A quantitative assay should be used for monitoring, preferably with the same method used in diagnosis and performed by the same laboratory 4
Always use anti-dsDNA and complement levels in patient follow-up, even if they were negative/normal in previous monitoring visits 4
Be aware that some patients lack correlation between serological results and clinical characteristics (serologically active but clinically quiescent SLE) 4

The guideline advises that anti‑dsDNA testing should not be performed when ANA is negative unless there is strong clinical suspicion of lupus. 7
Crithidia luciliae immunofluorescence (CLIFT) is recommended as the gold‑standard confirmatory assay for anti‑dsDNA antibodies, particularly important in patients with a negative ANA. 7
Anti‑nucleosome antibody testing shows roughly 83 % sensitivity and 97 % specificity for systemic lupus erythematosus and may become positive before ANA during disease development. 7

Periodic clinical monitoring is essential because autoantibodies can be detected long before clear clinical signs appear. 7
When the initial work‑up does not yield a definitive diagnosis, repeat serological testing after six months is recommended to assess for evolution of the antibody profile. 7